# Safety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002)

> **NCT05382364** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Pfizer** · enrollment: 25 (actual)

## Conditions studied

- Metastatic HER2+ Advanced Breast Cancer
- Breast Neoplasms
- Gastric or Gastroesophageal Junction Adenocarcinoma (GEC)
- Colorectal Cancer

## Interventions

- **DRUG:** Tucatinib

## Key facts

- **NCT ID:** NCT05382364
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-06-29
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2026-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05382364

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05382364, "Safety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002)". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05382364. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*